Clinical trials: Reperfusion
Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery
Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass
Around 7500 neonates born yearly in the United States have complex congenital heart disease that require surgical repair in the first few days of life.
- Trial name
- NCT02151877
- Testing
- Inhaled Nitric Oxide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Congenital Heart Disease
Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
Each year, there are over 400,000 cardiac surgical operations performed in the United States; of which 10,000 are performed on children.
- Trial name
- NCT00585013
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Myocardial Infarction, Reperfusion Injury
Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries.
- Trial name
- NCT00265239
- Testing
- edaravone
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Kumamoto University
COVID-19, Myocardial Reperfusion Injury
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system.
- Conditions
- COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
- Trial name
- NCT04397939
- Where
- United States
- Volunteers
- 4,695 people
- Sponsor
- Icahn School of Medicine at Mount Sinai